RecruitingNCT07300969
DT-101 compared with placebo for adult depression
About this title
Read the official source — NCT07300969This study evaluates the safety and effectiveness of DT-101 for people with depression.
Medication studyAges 18–75Multiple countries
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of DT-101 for people with depression.
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.
What will I do during this study?
Participants are randomly assigned to one of two DT-101 dose groups or placebo (an inactive comparison treatment). Clinic visits occur about every two weeks and include health checks and questionnaires; the study also includes physical and neurological exams, blood and urine samples, clinical assessments and blood sampling to study how the medicine is processed.
- Listed locations
- Bentonville and 42 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: December 16, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 300
- Sponsor
- Draig Therapeutics Ltd
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, United Kingdom, Bulgaria, ...
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT07300969
- Official title
Show the full official title
A Phase 2 Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder (MDD)
Recruitment & locations
RecruitingBentonville, United States · Little Rock, United States · Oceanside, United States
36 more locations
- San Diego, United States
- Torrance, United States
- Miami, United States
- New Port Richey, United States
- Orlando, United States
- Atlanta, United States
- Decatur, United States
- Gaithersburg, United States
- Watertown, United States
- Flowood, United States
- Las Vegas, United States
- Marlton, United States
- New York, United States
- Media, United States
- Austin, United States
- DeSoto, United States
- Richardson, United States
- Wichita Falls, United States
- Bellevue, United States
- Kazanlak, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Vratsa, Bulgaria
- Ostrava, Czechia
- Prague, Czechia
- Říčany, Czechia
- Gdansk, Poland
- Katowice, Poland
- Poznan, Poland
- Chester, United Kingdom
- Eastbourne, United Kingdom
- Glasgow, United Kingdom
- London, United Kingdom
- Nottingham, United Kingdom
- Oxford, United Kingdom
- Czechia
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of DT-101 for people with depression.
Who is behind this study?
The study sponsor is Draig Therapeutics Ltd.
Does this study involve medication?
Yes. The study involves medication, including DT-101 and Placebo.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
